Rallybio Corp, a clinical-stage biotech focused on rare and severe diseases, showed improved financial metrics in 2025 alongside encouraging Phase 1 data for its lead candidate RLYB116 targeting complement dysregulation. The company's recent merger agreement with Candid introduces a substantial capital injection of $505.5 million and diversifies its pipeline with T-cell engager therapies for autoimmune disorders. Despite operational losses and regulatory challenges typical of early-stage biotechs, Rallybio’s strategic moves position it for potential expansion pending successful clinical and regulatory milestones.